Ebola Vaccine Trials in Guinea
The number of Ebola Virus Disease cases continues to fluctuate in Guinea. At the same time phase 1 studies of vaccine candidates have produced promising immunogenicity and safety results. These vaccines now need to be evaluated further for safety, efficacy and effectiveness.
Matthias Egger, Sven Trelle and Stefanie Hossmann from ISPM and CTU Bern have contributed to the design of two trials, a randomized ring vaccination trial and a single-arm trial, in Guinea, under the auspices of the World Health Organization. The ring vaccination trial will be performed as a randomized phase 3 trial to evaluate the efficacy, effectiveness and safety of one dose of VSV-EBOV vaccine in the prevention of EVD when implemented as ring vaccination.
CTU Bern and ISPM are responsible for the data management and statistical analysis, together with colleagues at WHO, the Norwegian Public Health Institute, the London School of Hygiene and Tropical Medicine and the University of Florida. The trial is implemented by Médecins Sans Frontières who have been supporting the Ebola response in Guinea since the start of the epidemic.